← Back to Clinical Trials
Recruiting NCT06230861

NCT06230861 Effects of Quercetin on Cardiometabolic Outcomes

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06230861
Status Recruiting
Phase
Sponsor University of Central Lancashire
Condition Cardiometabolic Syndrome
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2024-03-01
Primary Completion 2026-08-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
QuercetinPlacebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2024-03-01 with a primary completion date of 2026-08-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Quercetin may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.

Eligibility Criteria

Inclusion Criteria: * Healthy * Between 18 \& 65 years * Non-smoker * BMI \< 30 * Able to give informed consent Exclusion Criteria: * Pregnancy * Diabetes or any other metabolic/ uncontrolled hypertensive conditions * Food allergies to quercetin * Habitual consumption of quercetin * Not regularly taking medication or antioxidant supplements

Contact & Investigator

Central Contact

Jonathan Sinclair, PhD, DSc

✉ jksinclair@uclan.ac.uk

📞 +447875651533

Frequently Asked Questions

Who can join the NCT06230861 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Cardiometabolic Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06230861 currently recruiting?

Yes, NCT06230861 is actively recruiting participants. Contact the research team at jksinclair@uclan.ac.uk for enrollment information.

Where is the NCT06230861 trial being conducted?

This trial is being conducted at Preston, United Kingdom.

Who is sponsoring the NCT06230861 clinical trial?

NCT06230861 is sponsored by University of Central Lancashire. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology